TEL AVIV, Israel and BETHESDA, MD., May 5, 2022 /PRNewswire/ — CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cannabinoid-based cancer drugs, today announced that it has received a Grant of patent notice of the Patent Register, Department of Intellectual Property, Government of the Hong Kong Special Administrative Region. This notice concerns the Company’s patent entitled: System and method for high throughput cancer cell screening.
The company further indicated that it believes the grant of this patent by the Hong Kong Patent Registry validates its innovative approach to drug discovery using data obtained from high-throughput screening (HTS) of compounds on various cancer cell types to elucidate and identify compounds that are most effective as anti-cancer agents.
This process has already been instrumental for the Company in producing several promising drug candidates for the treatment of cancer, which are now at various stages of the regulatory pathway, including its new drug candidate RCC-33 for the treatment colorectal cancer.
About CNBX Pharmaceuticals:
CNBX Pharmaceuticals Inc. (OTCQB: CNBX) is an American public company and a world leader in the development of cancer-related cannabinoid drugs. The Company’s R&D is based in Israel, where he is authorized by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cnbxpharma.com. For the latest updates on CNBX Pharmaceuticals, follow the company on Twitter @cnbxpharma, Facebook @cnbxPharmaceuticals, LinkedInand Instagram @CNBX_Pharmaceuticals.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other US federal securities laws. Such statements include, but are not limited to, statements identified by words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”. , “target”, “project” and similar expressions. The statements in this release are based on the current beliefs and expectations of the management of our company and are subject to significant risks and uncertainties. Actual results may differ from those described in the forward-looking statements. Many factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, challenges inherent in new product development initiatives, the effect of any product competitor, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is needed to maintain our business, changes in government policy and regulation, potential litigation by or against us, any government reviews of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our most recent 10-Q Report deposit April 12, 2022. We undertake no obligation to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about CNBX Pharmaceuticals Inc. approved by the Company come from the Company itself and bear our name as the source.
For more information about CNBX, please contact us:
CNBX Pharmaceuticals Inc.
+1 (877) 424-2429
SOURCECNBX Pharmaceuticals Inc.